Review



gene-chip genotyping approach  (23andMe)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    23andMe gene-chip genotyping approach
    Gene Chip Genotyping Approach, supplied by 23andMe, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/customised+oligonucleotide+microarray/genotyping+array/pmc03422723-76-7-4
    Average 90 stars, based on 1 article reviews
    gene-chip genotyping approach - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Microarray:

    Article Title: Influence of autozygosity on common disease risk across the phenotypic spectrum.
    Article Snippet: .. In 23andMe, sex was similarly genetically inferred via genotype microarray data. .. G&H, UK Biobank, and Saudi Arabian cohorts genotype data preparation We used the 2021 July data release of the G&H data, which contained 46,132 individuals genotyped on the Illumina Global Screening Array v3EAMD (GRCh38).

    Article Title: Chromosomal phase improves aneuploidy detection in non-invasive prenatal testing at low fetal DNA fractions
    Article Snippet: Microarray genotype data for three of the grandparents of the fetus were available through 23andMe , AncestryDNA , and FamilyTreeDNA . .. Microarray genotype data for three of the grandparents of the fetus were available through 23andMe , AncestryDNA , and FamilyTreeDNA . ..

    other:

    Article Title: Lack of causal association between heart failure and osteoporosis: a Mendelian randomization study
    Article Snippet: Fracture [ ] , UK Biobank and 23andMe cohorts , 1,214,434 , Age, sex, genotyping array, assessment center and ancestry informative principal components 1 to 20 , European.

    Article Title: Relevance of Pharmacogenomics to the Safe Use of Antimicrobials.
    Article Snippet: CYP2C19, which is relevant to voriconazole use, is also part of a “direct to the consumer” genotyping panel (https://www.23andme.com/en-gb/test-info/pharmacogenetics/, accessed on 7 February 2023).

    Article Title: Interaction of Mitochondrial Polygenic Score and Lifestyle Factors in LRRK2 p.Gly2019Ser Parkinsonism.
    Article Snippet: Fox Foundation (MJFF) and the genetic data (array-based genotyping) were provided by 23andMe, as previously described.28 All patients with PD included from the Fox Insight cohort in this study were of self-reported European ancestry.

    Article Title: Influence of autozygosity on common disease risk across the phenotypic spectrum
    Article Snippet: The 23andMe cohort is a prospective cohort of over 8 million research consented individuals, with genotype array and self-reported phenotype data.

    Article Title: Relevance of Pharmacogenomics to the Safe Use of Antimicrobials
    Article Snippet: CYP2C19, which is relevant to voriconazole use, is also part of a “direct to the consumer” genotyping panel ( https://www.23andme.com/en-gb/test-info/pharmacogenetics/ , accessed on 7 February 2023).

    Activity Assay:

    Article Title: Proteomic insights into the associations between obesity, lifestyle factors, and coronary artery disease
    Article Snippet: .. Trait Adjustments PMID Body mass index Age, sex, and genetic 1–5 principal components 30239722 Waist-to-hip ratio Age, sex, and genetic 1–5 principal components 30239722 Waist circumference Age and study-specific covariates 25673412 Visceral adipose tissue Age, sex, batch and the first ten principal components 31501611 Smoking initiation Age, sex, and the first ten genetic principal components 30643251 Lifetime smoking index Genotyping chip and sex 31689377 Alcohol drinking Age, sex, and the first ten genetic principal components 30643251 Alcohol dependence Sex and 1-5 principal components 30482948 Coffee consumption Age, sex, body mass index, total energy, proportion of typical food intake, and 20 genetic principal components 31046077 Caffeine consumption Age, sex, study-site, fasting status, smoking status, and genetic principal components 27702941 Moderate-to-vigorous physical activity Age, sex, age-squared, principal components reflecting population structure 36071172 Vigorous physical activity Age, sex, genotyping chip, first ten genomic principal components, and center 29899525 Sedentary behavior Age-squared, age, sex, age-sex interaction, and the first 30 principal components 32317632 Leisure screen time Age, sex, age-squared, principal components reflecting population structure 36071172 Sleep duration Age, sex, and 10 principal components 30846698 Insomnia Age, sex, genotype array, and 10 genetic principal components in the UK Biobank; age, sex and the top five principal components in 23andMe 30804565 Supplemental Table 2. ..



    Similar Products

    customised oligonucleotide microarray  (Agilent technologies)
    90
    Agilent technologies customised oligonucleotide microarray
    Customised Oligonucleotide Microarray, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/customised+oligonucleotide+microarray/pm25195018-60-10-12
    Average 90 stars, based on 1 article reviews
    customised oligonucleotide microarray - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    customised 11 kb oligonucleotide-microarray  (Agilent technologies)
    90
    Agilent technologies customised 11 kb oligonucleotide-microarray
    Relative expression levels of GATA-4 and friend-of-GATA ( FOG )-2 according to <t>microarray</t> analyses. ( A – D ) GATA-4 and ( E – H ) FOG-2 . ( A and E ) MYCN -nonamplified ( n =218) vs MYCN -amplified ( n =32 for GATA-4 ; n =33 for FOG-2 ). ( B and F ) Localised stages ( n =153) vs stage 4 ( n =67) vs stage 4S ( n =31). ( C and G ) Patients below 1 year ( n =94) vs above 1 year ( n =157). ( D and H ) High-risk (HR; n =82) vs low-risk (LR; n =169) tumours according to the PAM classification. Expression values are given in log ratios (sample vs reference RNA). Boxes: median expression values (horizontal line) and twenty-fifth and seventy-fifth percentiles; whiskers: distances from the end of the box to the largest and smallest observed values that are <1.5 box lengths from either end of the box; open circles: outlying values; asterisks: extreme values. ** P <0.01; *** P <0.001 according to the nonparametric Mann–Whitney test.
    Customised 11 Kb Oligonucleotide Microarray, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/customised+oligonucleotide+microarray/pmc02768442-36-29-31
    Average 90 stars, based on 1 article reviews
    customised 11 kb oligonucleotide-microarray - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Relative expression levels of GATA-4 and friend-of-GATA ( FOG )-2 according to microarray analyses. ( A – D ) GATA-4 and ( E – H ) FOG-2 . ( A and E ) MYCN -nonamplified ( n =218) vs MYCN -amplified ( n =32 for GATA-4 ; n =33 for FOG-2 ). ( B and F ) Localised stages ( n =153) vs stage 4 ( n =67) vs stage 4S ( n =31). ( C and G ) Patients below 1 year ( n =94) vs above 1 year ( n =157). ( D and H ) High-risk (HR; n =82) vs low-risk (LR; n =169) tumours according to the PAM classification. Expression values are given in log ratios (sample vs reference RNA). Boxes: median expression values (horizontal line) and twenty-fifth and seventy-fifth percentiles; whiskers: distances from the end of the box to the largest and smallest observed values that are <1.5 box lengths from either end of the box; open circles: outlying values; asterisks: extreme values. ** P <0.01; *** P <0.001 according to the nonparametric Mann–Whitney test.

    Journal: British Journal of Cancer

    Article Title: GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes

    doi: 10.1038/sj.bjc.6605276

    Figure Lengend Snippet: Relative expression levels of GATA-4 and friend-of-GATA ( FOG )-2 according to microarray analyses. ( A – D ) GATA-4 and ( E – H ) FOG-2 . ( A and E ) MYCN -nonamplified ( n =218) vs MYCN -amplified ( n =32 for GATA-4 ; n =33 for FOG-2 ). ( B and F ) Localised stages ( n =153) vs stage 4 ( n =67) vs stage 4S ( n =31). ( C and G ) Patients below 1 year ( n =94) vs above 1 year ( n =157). ( D and H ) High-risk (HR; n =82) vs low-risk (LR; n =169) tumours according to the PAM classification. Expression values are given in log ratios (sample vs reference RNA). Boxes: median expression values (horizontal line) and twenty-fifth and seventy-fifth percentiles; whiskers: distances from the end of the box to the largest and smallest observed values that are <1.5 box lengths from either end of the box; open circles: outlying values; asterisks: extreme values. ** P <0.01; *** P <0.001 according to the nonparametric Mann–Whitney test.

    Article Snippet: In brief, 1 μ g of linearly amplified Cy3- and Cy5-labelled cRNA was hybridised together with 1 μ g of reverse colour Cy-labelled reference cRNA to a customised 11 kb oligonucleotide-microarray (Agilent Technologies, Waldbronn, Germany).

    Techniques: Expressing, Microarray, Amplification, MANN-WHITNEY

    Relative expression levels of GATA-2 and -3 according to microarray analyses. ( A – D ) GATA-2 and ( E – H ) GATA-3 . ( A and E ) MYCN -nonamplified ( n =218) vs MYCN -amplified ( n =33). ( B and F ) Localised stages ( n =153) vs stage 4 ( n =67) vs stage 4S ( n =31). ( C and G ) Patients below 1 year ( n =94) vs above 1 year ( n =157). ( D and H ) High-risk (HR; n =82) vs low-risk (LR; n =169) tumours according to the PAM classification. Expression values are given in log ratios (sample vs reference RNA). Box plots represent data as in . * P <0.05; ** P <0.01; *** P <0.001 according to the nonparametric Mann–Whitney test.

    Journal: British Journal of Cancer

    Article Title: GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes

    doi: 10.1038/sj.bjc.6605276

    Figure Lengend Snippet: Relative expression levels of GATA-2 and -3 according to microarray analyses. ( A – D ) GATA-2 and ( E – H ) GATA-3 . ( A and E ) MYCN -nonamplified ( n =218) vs MYCN -amplified ( n =33). ( B and F ) Localised stages ( n =153) vs stage 4 ( n =67) vs stage 4S ( n =31). ( C and G ) Patients below 1 year ( n =94) vs above 1 year ( n =157). ( D and H ) High-risk (HR; n =82) vs low-risk (LR; n =169) tumours according to the PAM classification. Expression values are given in log ratios (sample vs reference RNA). Box plots represent data as in . * P <0.05; ** P <0.01; *** P <0.001 according to the nonparametric Mann–Whitney test.

    Article Snippet: In brief, 1 μ g of linearly amplified Cy3- and Cy5-labelled cRNA was hybridised together with 1 μ g of reverse colour Cy-labelled reference cRNA to a customised 11 kb oligonucleotide-microarray (Agilent Technologies, Waldbronn, Germany).

    Techniques: Expressing, Microarray, Amplification, MANN-WHITNEY